InsiderTrades

Form 4 for JBIO Jade Biosciences, Inc.

Accepted 2023-05-19 00:00:00 ET · period of report 2023-05-17 · accession 0001415889-23-008425 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2023-05-19 2023-05-17 JBIO Gillies Hunter Chief MEDICAL Off S - Sale+OE $19.59 -1,090 3,251 -25% -$21.4K
D 2023-05-19 2023-05-17 JBIO Gillies Hunter Chief MEDICAL Off M - OptEx $1.74 +1,090 4,341 +34% +$1,897
D 2023-05-19 2023-05-17 JBIO Gillies Hunter Chief MEDICAL Off M - OptEx $0.00 -1,090 19.0K -5% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-05-17 S D 1,090 $19.59 3,251 D — — (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.50 to $19.665, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
2 Common Common Stock 2023-05-17 M A 1,090 $1.74 4,341 D — — (F2) Includes 1,291 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2023 in a transaction that is exempt under Rule 16b-3(c) and 16b3(d).
3 Derivative Stock Option (Right to Buy) 2023-05-17 M D 1,090 $0.00 19,018 D $1.74 · — to 2030-09-03 1,090 Common Stock (F4) A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.